Primary Systemic Therapy of Breast Cancer
- 1 June 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 11 (6) , 574-589
- https://doi.org/10.1634/theoncologist.11-6-574
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the rationale for using primary systemic therapy (PST) in the treatment of nonmetastatic breast cancer.Discuss the pathologic complete response (pCR) rate as a surrogate marker of PST benefit.Select the most appropriate regimen for a patient with breast cancer considered for PST.Explain the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients. Access and take the CME test online and receive 1 AMA PRA category 1 credit at CME.TheOncologist.comKeywords
This publication has 104 references indexed in Scilit:
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBritish Journal of Cancer, 2004
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- The Sentinel Node in Breast Cancer — A Multicenter Validation StudyNew England Journal of Medicine, 1998
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: Preliminary results of a randomised trial: S6European Journal Of Cancer, 1994
- Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 1988